SERPINA12
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| serpin family A member 12 | MIM:617471 | Ensembl:ENSG00000165953 | HGNC:HGNC:18359 | PA134863157 | 14q32.13 |
GO terms in SERPINA12
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IBA | GO:0004867 | serine-type endopeptidase inhibitor activity |
| BP | IBA | GO:0010951 | negative regulation of endopeptidase activity |
| BP | IEA | GO:0010951 | negative regulation of endopeptidase activity |
| BP | IEA | GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling |
| BP | IEA | GO:0045721 | negative regulation of gluconeogenesis |
| BP | IEA | GO:0046628 | positive regulation of insulin receptor signaling pathway |
| BP | IEA | GO:0051055 | negative regulation of lipid biosynthetic process |
| BP | IEA | GO:0090181 | regulation of cholesterol metabolic process |
| BP | IEA | GO:0090207 | regulation of triglyceride metabolic process |
| CC | IBA | GO:0005615 | extracellular space |
| CC | IEA | GO:0005886 | plasma membrane |
Gene expression in normal tissue: SERPINA12
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in SERPINA12
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD144 | NSC95397 | 3 |
| iGMDRD123 | Isoevodiamine | 3 |
| iGMDRD394 | BX-795 | 1 |
| iGMDRD945 | ML214 | 6 |
| iGMDRD883 | CIL55A | 4 |
| iGMDRD193 | Fqi1 | 6 |
| iGMDRD698 | Neratinib | 3 |
| iGMDRD289 | Parthenolide | 3 |
| iGMDRD105 | Triptolide | 3 |
| iGMDRD121 | GMX1778 | 3 |
| iGMDRD138 | PX 12 | 6 |
| iGMDRD251 | ML162 | 6 |
| iGMDRD260 | FQI-2 | 3 |
| iGMDRD64 | Parbendazole | 6 |
| iGMDRD246 | NPC26 | 3 |
| iGMDRD188 | Piperlongumine | 3 |
| iGMDRD577 | BIX01294 | 3 |
| iGMDRD329 | Merck60 | 6 |
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in SERPINA12

